In-article:

Abivax announces the holding of an ordinary and extraordinary ad hoc Meeting on November 9, 2022. – 03/10/2022 at 18:05


ABIVAX press release

Abivax announces the holding of an ordinary and extraordinary ad hoc Meeting on November 9, 2022.

Abivax SA, a clinical-stage Phase 3 biotechnology company developing novel immune-modulating drugs to treat inflammatory diseases, viral diseases and cancer, today announces that an ad hoc Ordinary and Extraordinary General Meeting (l ‘ “General Meeting”) will be held on November 9, 2022 at 10:00 a.m. at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008).



Source link -86